About TTX

Halneuron™ (Tetrodotoxin or TTX) is a small molecule, targeting moderate severe neuropathic pain without the side effects associated with opioid use. TTX blocks the voltage-gated sodium channels (VGSCs) found on nerves which conduct pain impulses, which are known to be affected in chronic pain conditions. TTX is highly specific to VGSCs on the periphery without effects on the central nervous system.

The current gold standard for moderate to severe pain treatment is opioids, representing a market opportunity of more than $7 billion worldwide each year. However, opioids have limitations. Serious risk factors associated with opioids include respiratory, gastrointestinal and central nervous system side effects. Opioids can also be ineffective - one in four patients fail opioid treatment. Finally, opioids have a risk of addiction and tolerance, which is a limiting factor in prescribing this class of drugs.

Halneuron is 3000 times more potent than morphine without the opioid-like side effects. It is non-addictive, with no tolerance issues, with a long duration of pain relief. WEX has completed 15 clinical trials with Halneuron, with more than 700 subjects treated to date. Current data has demonstrated Halneuron to be safe and well-tolerated.

Our first indication is for pain associated with Chemotherapy Induced Neuropathic Pain (CINP) with phase 3 trials planned for the US and Canada. WEX has filed a protocol with the U.S. Food and Drug Administration (FDA) and health Canada for our lead indication planning for the launch of the pivotal trials in 2018. This is a randomized, double-blind, dose-finding, placebo-controlled, multicenter study of the potential efficacy and safety of TTX in patients with CINP.  WEX has completed one phase 3 Clinical Trial in Canada for Cancer Related Pain.